Supernus SVP reports equity award moves

Supernus Pharmaceuticals executive Jonathan Rubin, SVP and Chief Medical Officer, reported equity award activity and related share transactions.

Rhea-AI Filing Summary

Supernus Pharmaceuticals executive Jonathan Rubin, SVP and Chief Medical Officer, reported equity award activity and related share transactions. He disposed of 1,250 restricted stock units back to the issuer and simultaneously acquired 1,250 shares of common stock at $0.00 per share as a grant. To cover taxes on the RSU vesting, 675 shares of common stock were automatically disposed of at $50.69 per share, with the company withholding these shares to satisfy tax obligations. Following these transactions, Rubin directly owned 13,341 shares of Supernus common stock.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Rubin Jonathan

Role SVP, Chief Medical Officer

Type	Security	Shares	Price	Value
Disposition	Restricted Stock Unit	1,250	$0.00	$0.00
Grant/Award	Common Stock	1,250	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	675	$50.69	$34K

Holdings After Transaction: Restricted Stock Unit — 1,250 contracts (Direct); Common Stock — 13,341 shares (Direct)

Footnotes (3)

1. F1. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
2. F2. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
3. F3. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Supernus (SUPN) executive Jonathan Rubin report?

Jonathan Rubin reported disposing 1,250 restricted stock units to the issuer, receiving 1,250 shares of Supernus common stock as a grant, and an automatic tax-withholding disposition of 675 shares at $50.69 per share related to RSU vesting, all held as direct ownership.

How many Supernus (SUPN) shares does Jonathan Rubin own after these Form 4 transactions?

After the reported transactions, Jonathan Rubin directly owns 13,341 shares of Supernus common stock. This total reflects the 1,250-share grant he acquired and the 675 shares withheld for taxes in connection with restricted stock unit vesting on the reported transaction date.

Were any of Jonathan Rubin’s Supernus (SUPN) share moves open-market buys or sells?

The filing shows no open-market buys or sells. Rubin received 1,250 shares as a grant and had 675 shares disposed of to cover tax withholding on RSU vesting, a non-market transaction handled directly with the company rather than through market trading.

What does the tax-withholding disposition in Jonathan Rubin’s Supernus (SUPN) filing mean?

The tax-withholding disposition reflects 675 Supernus shares delivered at $50.69 per share to satisfy tax obligations from RSU vesting. Instead of paying cash, shares are withheld by the company, which is a common administrative mechanism and not a discretionary open-market sale by the insider.

How are Jonathan Rubin’s restricted stock units (RSUs) in Supernus (SUPN) structured?

Each restricted stock unit represents one share of Supernus common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 23, 2024, and are settled in common stock, aligning Rubin’s compensation with the company’s equity performance over multiple years.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rubin Jonathan

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		A		1,250	A	$0	14,016	D
Common Stock	02/25/2026		F		675(1)	D	$50.69	13,341	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(2)	02/25/2026		D			1,250	(3)	(3)	Common Stock	1,250	$0	1,250	D

Explanation of Responses:

1. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.

2. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

3. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.